argenx

argenx is a global biopharmaceutical company dedicated to developing life-changing immunology solutions for people suffering from severe autoimmune diseases. Through its Immunology Innovation Program (IIP) and partnerships with leading academic researchers, argenx translates immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. The company has developed and commercialized the first-and-only approved neonatal Fc receptor (FcRn) blocker in the U.S., Japan, Israel, the EU, and the UK, known as VYVGART (efgartigimod alfa) and VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). argenx also investigates empasiprubart for severe IgM-driven autoimmune diseases. This innovation ecosystem fosters collaboration between pioneering scientists and antibody engineers to accelerate the discovery and development of advanced therapies.